Crinetics Pharmaceuticals CRNX 深 沪
等待开盘 05-21 09:30:00 美东时间
36.345
+1.405
+4.02%
华盛通- 最 高36.55
- 今 开35.24
- 成交量 46.30万股
- 最 低 35.23
- 昨 收 34.94
- 总市值 38.32亿
- 52周最高 57.99
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 25.83
- 委 比 -5.08%
- 总股本 1.05亿
- 历史最高 62.53
- 量 比 0.45
- 振 幅 3.78%
- 历史最低 10.63
- 每 手 1
- 风险率 7.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Evercore ISI Group Maintains Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $88
Evercore ISI Group analyst Maneka Mirchandaney maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Outperform and lowers the price target from $89 to $88.
05-16 01:31
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Citizens Maintains Market Outperform on Crinetics Pharmaceuticals, Lowers Price Target to $95
Citizens analyst Jonathan Wolleben maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Market Outperform and lowers the price target from $97 to $95.
05-08 22:31
财报速睇 | Crinetics Pharmaceuticals 2026财年Q1营收0.11亿美元，同比增长2873.4%；归母净利润亏损1.28亿美元，同比亏损扩大32.1%
华盛资讯5月8日讯，Crinetics Pharmaceuticals公布2026财年Q1业绩，公司Q1营收0.11亿美元，同比增长2873.4%，归母净利润亏损1.28亿美元，同比亏损扩大32.1%。
05-08 11:21
财报速睇 | Crinetics Pharmaceuticals 2026财年Q1营收0.11亿美元，同比增长2873.4%；归母净利润亏损1.28亿美元，同比亏损扩大32.1%
华盛资讯5月8日讯，Crinetics Pharmaceuticals公布2026财年Q1业绩，公司Q1营收0.11亿美元，同比增长2873.4%，归母净利润亏损1.28亿美元，同比亏损扩大32.1%。
05-08 07:29
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
Crinetics Pharmaceuticals Obtains European Commission Approval For PALSONIFY For The Treatment Of Acromegaly in Adults; Crinetics' First Regulatory Approval Outside Of The U.S., With First Launch Planned For Germany And Austria
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2
04-28 05:15
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
Crinetics Pharmaceuticals announced the European Commission's approval of PALSONIFY (paltusotine) as the first once-daily, oral therapy for acromegaly in the EU. The approval is supported by Phase 3 trials showing rapid efficacy, safety, and symptom reduction. PALSONIFY is already approved in the U.S. and has orphan drug designation in the EU. Commercialization starts in Germany and Austria, with plans for Brazil and Japan.
04-27 21:13
